Loading...
•
Dec 31, 2021
Nkarta Q4 2021 Earnings Report
Nkarta reported financial results for the fourth quarter and year ended December 31, 2021.
Key Takeaways
Nkarta reports a net loss of $22.8 million, or $0.69 per basic and diluted share, for the fourth quarter of 2021. As of December 31, 2021, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $240.2 million.
On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022
NKX101 received orphan drug designation (ODD) for the treatment of acute AML from the FDA in December 2021.
Nkarta is producing clinical supply of NKX019 at its in-house cGMP clinical manufacturing facility in South San Francisco, California.
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...